Timing dilemma: a systematic review and meta-analysis of short-term mortality in patients with COVID-19 undergoing tracheostomy with varied timing, including 7, 10 and 14 days.

Publication date: Dec 10, 2024

To analyse the effects of tracheostomy timing on COVID-19 outcomes by comparing mortality rates at different time points (7, 10 and 14 days). Systematic review and meta-analysis. PubMed, Embase, Cochrane Library, Web of Science and Scopus were searched from 31 August 2023 to 6 September 2023. The primary outcome was short-term mortality, defined as intensive care unit (ICU) mortality, hospital mortality and 28-day or 30-day mortality. The secondary outcomes included mechanical ventilation duration, ICU and hospital days. Among 3465 patients from 12 studies, the 10-day subgroup analysis revealed higher mortality for earlier tracheostomy than for later tracheostomy (49. 7% vs 32. 6%, OR 1. 91, 95% CI 1. 37-2. 65). No significant differences were observed at 7- and 14-day marks. Earlier tracheostomy was associated with shorter mechanical ventilation (mean difference=-7. 35 days, 95% CI -11. 63 to -0. 38) and ICU stays (mean difference=-11. 24 days, 95% CI -18. 50 to -3. 97) compared with later tracheostomy. Regarding hospital stay, the later tracheostomy group exhibited a trend towards longer-term inpatients, with no significant difference. No significant difference in short-term mortality was observed between patients undergoing tracheostomy at 7 and 14 days; however, at 10 days, later tracheostomy resulted in a lower mortality rate. Accordingly, subtle timing differences may impact short-term results in COVID-19 patients. Considering that the later tracheostomy group had longer mechanical ventilation and ICU stays, additional research is required to determine an optimal timing that reduces mortality cost-effectively.

Open Access PDF

Concepts Keywords
35days COVID-19
August COVID-19
Covid Head & neck surgery
Inpatients Hospital Mortality
Humans
INTENSIVE & CRITICAL CARE
Intensive Care Units
Length of Stay
Pulmonary Disease
Respiration, Artificial
Respiratory Distress Syndrome
SARS-CoV-2
SARS-CoV-2 Infection
Time Factors
Tracheostomy

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Dihydrotachysterol
drug DRUGBANK Tocilizumab
disease MESH infections
disease MESH complications
disease MESH laryngeal stenosis
disease MESH fistulas
disease IDO process
drug DRUGBANK Methionine
disease MESH respiratory failure
disease IDO country
disease IDO quality

Original Article

(Visited 1 times, 1 visits today)